Rani Therapeutics Appoints New Director, Board Changes
Ticker: RANI · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, appointment, governance
TL;DR
Rani Therapeutics adds a new director to its board.
AI Summary
Rani Therapeutics Holdings, Inc. announced on October 22, 2025, a change in its board of directors. Specifically, Dr. David S. Leo has been appointed as a new director, effective immediately. The company also disclosed information regarding compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns board appointments and compensatory arrangements, which are routine corporate governance events.
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Registrant
- Dr. David S. Leo (person) — Newly appointed director
- October 22, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to Rani Therapeutics Holdings, Inc.'s board?
Dr. David S. Leo has been appointed as a new director.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 22, 2025.
What is the principal executive office address for Rani Therapeutics Holdings, Inc.?
The address is 2051 Ringwood Avenue, San Jose, California, 95131.
What is the Standard Industrial Classification code for Rani Therapeutics Holdings, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the exact name of the registrant as specified in its charter?
The exact name is RANI THERAPEUTICS HOLDINGS, INC.
Filing Stats: 1,539 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2025-10-27 06:03:21
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value RANI The Nasdaq Stock Mar
Filing Documents
- d935516d8k.htm (8-K) — 33KB
- 0001193125-25-250614.txt ( ) — 148KB
- rani-20251022.xsd (EX-101.SCH) — 3KB
- rani-20251022_lab.xml (EX-101.LAB) — 18KB
- rani-20251022_pre.xml (EX-101.PRE) — 11KB
- d935516d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 27, 2025 Rani Therapeutics Holdings, Inc. By: / S / S VAI S ANFORD Name: Svai Sanford Title: Chief Financial Officer